Entering text into the input field will update the search result below

Sarepta Therapeutics net loss widens in Q2

  • Sarepta Therapeutics (NASDAQ:SRPT +0.3%) Q2 results: Revenues: $0; R&D Expense: $44.3M (+51.7%); G&A: $17.8M (+38.0%); Operating Loss: ($62.1M) (-47.5%); Net Loss: ($62.3M) (-48.7%); Loss Per Share: ($1.35) (-33.7%); Non-GAAP Loss Per Share: ($1.19) (-36.8%); Quick Assets: $123.2M (-36.0%).
  • No guidance given.

Recommended For You

About SRPT Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
SRPT--
Sarepta Therapeutics, Inc.